JP2022546878A5 - - Google Patents
Info
- Publication number
- JP2022546878A5 JP2022546878A5 JP2022540618A JP2022540618A JP2022546878A5 JP 2022546878 A5 JP2022546878 A5 JP 2022546878A5 JP 2022540618 A JP2022540618 A JP 2022540618A JP 2022540618 A JP2022540618 A JP 2022540618A JP 2022546878 A5 JP2022546878 A5 JP 2022546878A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutically acceptable
- isovaleric acid
- acceptable salt
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025128508A JP2025163134A (ja) | 2019-09-03 | 2025-07-31 | コンジュゲートされたヘプシジン模倣物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895201P | 2019-09-03 | 2019-09-03 | |
| US62/895,201 | 2019-09-03 | ||
| US202062983515P | 2020-02-28 | 2020-02-28 | |
| US62/983,515 | 2020-02-28 | ||
| US202063020945P | 2020-05-06 | 2020-05-06 | |
| US63/020,945 | 2020-05-06 | ||
| US202063059747P | 2020-07-31 | 2020-07-31 | |
| US63/059,747 | 2020-07-31 | ||
| PCT/US2020/049244 WO2021046246A1 (en) | 2019-09-03 | 2020-09-03 | Conjugated hepcidin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025128508A Division JP2025163134A (ja) | 2019-09-03 | 2025-07-31 | コンジュゲートされたヘプシジン模倣物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546878A JP2022546878A (ja) | 2022-11-09 |
| JP2022546878A5 true JP2022546878A5 (https=) | 2023-09-11 |
| JP7831841B2 JP7831841B2 (ja) | 2026-03-17 |
Family
ID=74681239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540618A Active JP7831841B2 (ja) | 2019-09-03 | 2020-09-03 | コンジュゲートされたヘプシジン模倣物 |
| JP2025128508A Pending JP2025163134A (ja) | 2019-09-03 | 2025-07-31 | コンジュゲートされたヘプシジン模倣物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025128508A Pending JP2025163134A (ja) | 2019-09-03 | 2025-07-31 | コンジュゲートされたヘプシジン模倣物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220372099A1 (https=) |
| EP (2) | EP4025592B1 (https=) |
| JP (2) | JP7831841B2 (https=) |
| KR (1) | KR20220075343A (https=) |
| CN (1) | CN114729022A (https=) |
| AU (1) | AU2020343328B2 (https=) |
| BR (1) | BR112022003999A2 (https=) |
| CA (1) | CA3152789A1 (https=) |
| DK (1) | DK4025592T3 (https=) |
| ES (1) | ES3058577T3 (https=) |
| FI (1) | FI4025592T3 (https=) |
| IL (1) | IL291030A (https=) |
| MX (1) | MX2022002633A (https=) |
| PH (1) | PH12022550510A1 (https=) |
| PL (1) | PL4025592T3 (https=) |
| WO (1) | WO2021046246A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2020014646A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| AU2022249095A1 (en) * | 2021-04-01 | 2023-10-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| IL309166A (en) * | 2021-06-14 | 2024-02-01 | Protagonist Therapeutics Inc | Pasidine mimesis for the treatment of hereditary hemochromatosis |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| EP4472996A4 (en) * | 2022-02-02 | 2025-11-26 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| WO2024011188A1 (en) * | 2022-07-07 | 2024-01-11 | Protagonist Therapeutics, Inc. | Combination therapy for treatment of iron overload diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CZ20013018A3 (cs) | 1999-03-17 | 2002-02-13 | Novo Nordisk A/S | Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina |
| US7094785B1 (en) * | 2002-12-18 | 2006-08-22 | Cornell Research Foundation, Inc. | Method of treating polycythemia vera |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| EP3129040A4 (en) | 2014-04-07 | 2018-03-21 | La Jolla Pharmaceutical Company | Hepdicin mimetic peptides and uses thereof |
| WO2015200916A2 (en) | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| UA123219C2 (uk) | 2015-10-23 | 2021-03-03 | Віфор (Інтернаціональ) Аґ | Інгібітори феропортину |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3509621A4 (en) | 2016-09-06 | 2020-06-17 | La Jolla Pharmaceutical Company | METHODS OF TREATING IRON OVERLOAD |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| CA3089868A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2020
- 2020-09-03 PH PH1/2022/550510A patent/PH12022550510A1/en unknown
- 2020-09-03 WO PCT/US2020/049244 patent/WO2021046246A1/en not_active Ceased
- 2020-09-03 FI FIEP20860676.4T patent/FI4025592T3/fi active
- 2020-09-03 EP EP20860676.4A patent/EP4025592B1/en active Active
- 2020-09-03 DK DK20860676.4T patent/DK4025592T3/da active
- 2020-09-03 US US17/639,138 patent/US20220372099A1/en not_active Abandoned
- 2020-09-03 US US17/011,844 patent/US20210061872A1/en active Pending
- 2020-09-03 CA CA3152789A patent/CA3152789A1/en active Pending
- 2020-09-03 CN CN202080076351.4A patent/CN114729022A/zh active Pending
- 2020-09-03 ES ES20860676T patent/ES3058577T3/es active Active
- 2020-09-03 JP JP2022540618A patent/JP7831841B2/ja active Active
- 2020-09-03 EP EP25211675.1A patent/EP4706671A3/en active Pending
- 2020-09-03 MX MX2022002633A patent/MX2022002633A/es unknown
- 2020-09-03 PL PL20860676.4T patent/PL4025592T3/pl unknown
- 2020-09-03 AU AU2020343328A patent/AU2020343328B2/en active Active
- 2020-09-03 BR BR112022003999A patent/BR112022003999A2/pt unknown
- 2020-09-03 KR KR1020227011086A patent/KR20220075343A/ko active Pending
-
2022
- 2022-03-01 IL IL291030A patent/IL291030A/en unknown
-
2025
- 2025-07-31 JP JP2025128508A patent/JP2025163134A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546878A5 (https=) | ||
| JP2024520861A5 (https=) | ||
| JP7831841B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP6039553B2 (ja) | エンドモルフィンのμオピオイド受容体アゴニスト類似体 | |
| AU2014228460B2 (en) | Pharmaceutical compositions | |
| US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
| US20230120030A1 (en) | Long-Acting Adrenomedullin Derivatives | |
| US20240293511A1 (en) | Hepcidin mimetics for treatment of hereditary hemochromatosis | |
| MX2014012625A (es) | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. | |
| JP2016515620A5 (https=) | ||
| PT1971362E (pt) | Exendina para tratamento de diabetes e redução do peso corporal | |
| CN102209553A (zh) | 肽制剂及其应用 | |
| WO2018128828A1 (en) | Novel hepcidin mimetics and uses thereof | |
| Klein et al. | Pressor and cardioaccelerator effects of gamma MSH and related peptides | |
| EP1976548B1 (en) | VIP fragments and compositions thereof | |
| WO2005016953A2 (en) | Antagonistic analogs of gh-rh (2003) | |
| WO1991010681A1 (en) | Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues | |
| WO2024011188A1 (en) | Combination therapy for treatment of iron overload diseases | |
| WO2007009359A1 (en) | Thymosin beta 4 derivatives and use thereof | |
| CA2543507A1 (en) | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions | |
| US6316414B1 (en) | Somatostatin analogs for the treatment of cancer | |
| JPH09502971A (ja) | Ｃｒｏｈｎ’ｓ病および／または潰瘍性大腸炎の治療もしくは予防 | |
| CN115414468B (zh) | 一种趋化素样因子1衍生肽在制备镇痛制剂中的应用 | |
| RU97107460A (ru) | Новые пептиды с иммуномодуляторным действием |